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The Role of Copper in Disulfiram-Induced Toxicity
and Radiosensitization of Cancer Cells
Colin Rae1, Mathias Tesson1, John W. Babich2, Marie Boyd3, Annette Sorensen3, and Robert J. Mairs1
1Radiation Oncology, Institute of Cancer Sciences, Cancer Research United Kingdom Beatson Laboratories, Glasgow, University of
Glasgow, Glasgow, United Kingdom; 2Molecular Insight Pharmaceuticals, Cambridge, Massachusetts; and 3Institute of Pharmacy
and Biomedical Sciences, Strathclyde University, Glasgow, United Kingdom
Disulfiram has been used for several decades in the treatment
of alcoholism. It now shows promise as an anticancer drug and
radiosensitizer. Proposed mechanisms of action include the in-
duction of oxidative stress and inhibition of proteasome activity.
Our purpose was to determine the potential of disulfiram to
enhance the antitumor efficacy of external-beam g-irradiation
and 131I-metaiodobenzylguanidine (131I-MIBG), a radiopharma-
ceutical used for the therapy of neuroendocrine tumors.Methods:
The role of copper in disulfiram-induced toxicity was investi-
gated by clonogenic assay after treatment of human SK-N-BE
(2c) neuroblastoma and UVW/NAT½AQ1 glioma cells. The synergistic
interaction between disulfiram and radiotherapy was evaluated
by combination-index analysis. Tumor growth delay was deter-
mined in vitro using multicellular tumor spheroids and in vivo
using human tumor xenografts in athymic mice. Results: Esca-
lating the disulfiram dosage caused a biphasic reduction in the
surviving fraction of clonogens. Clonogenic cell kill after treat-
ment with disulfiram concentrations less than 4 mM was cop-
per-dependent, whereas cytotoxicity at concentrations greater
than 10 mM was caused by oxidative stress. The cytotoxic ef-
fect of disulfiram was maximal when administered with equimo-
lar copper. Likewise, disulfiram radiosensitization of tumor cells
was copper-dependent. Furthermore, disulfiram treatment en-
hanced the toxicity of 131I-MIBG to spheroids and xenografts
expressing the noradrenaline transporter. Conclusion: The
results demonstrate that the cytotoxicity of disulfiram was cop-
per-dependent; the molar excess of disulfiram relative to cop-
per resulted in attenuation of disulfiram-mediated cytotoxicity;
copper was required for the radiosensitizing activity of disulfi-
ram; and copper-complexed disulfiram enhanced the efficacy
not only of external-beam radiation but also of targeted radio-
nuclide therapy in the form of 131I-MIBG. Therefore, disulfiram
may have anticancer potential in combination with radiother-
apy.
Key Words: disulfiram; copper; 131I-metaiodobenzylguanidine;
neuroblastoma radiosensitizer
J Nucl Med 2013; 54:1–8
DOI: 10.2967/jnumed.112.113324
Disulfiram ½AQ2, an inhibitor of aldehyde dehydrogenase (1),
has been used for the ½AQ3treatment of alcoholism for several
decades. This drug also has a variety of other ½AQ4actions that
suggest that it has potential as an anticancer agent. These
include the induction of oxidative stress (2,3), the genera-
tion of copper-dependent toxicity (2,4), proteasome inhibi-
tion (4–6), and NF-kB ½AQ5inhibition (7,8). Despite its diverse
range of pharmacologic activities, prolonged treatment with
disulfiram has negligible, reversible, adverse effects and is
considered a safe drug (9). Disulfiram is currently under-
going clinical trials for the treatment of various cancers
including melanoma and liver, lung, and prostate. To de-
termine the potential application of this agent in cancer
therapy, it is important to understand its mechanisms of
action and its effects in combination with other therapeutic
modalities.
Disulfiram-induced cytotoxicity has previously been
reported to be mediated by oxidative stress (2,3), which
may be enhanced by the presence of copper (2). Copper-
binding drugs have been shown to inhibit proteasome ac-
tivity (10) and generate reactive oxygen species (ROS) (11).
Disulfiram chelates copper, and it may be the disulfiram–
copper complex that is the toxic form of the drug (4). Many
tumors ½AQ6contain elevated levels of copper (10), possibly ren-
dering them selectively susceptible to disulfiram-induced
toxicity.
A potentially significant mechanism of disulfiram-
induced cell death involves inhibition of proteasome ac-
tivity. The proteasome degrades misfolded, superfluous, or
damaged proteins and controls many cellular processes
involved in differentiation, proliferation, signal transduc-
tion, cell cycle progression, and apoptosis. Proteasome
activity is increased in cancer cells, compared with normal
cells (12), and the proteasome inhibitor bortezomib is being
used in the treatment of multiple myeloma. Disulfiram has
been reported to inhibit proteasome activity and induce
apoptosis selectively in cancer cells but not normal cells
(4). The copper-binding activity of disulfiram may also be
involved in this mode of action because the formation of
organic copper complexes appears to be responsible for
proapoptotic proteasome inhibition (4). Other proteasome
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inhibitors (13), including the reduced form of disulfiram
(diethyldithiocarbamate) (14), have radiosensitizing effects,
and this may also apply to disulfiram, further increasing its
potential as an anticancer agent.
For tumor types that are both radiosensitive and chemo-
sensitive, such as neuroblastoma, combined chemotherapy
and radiotherapy may offer the best prospects for a positive
outcome to treatment. A feature of neuroblastoma is ex-
pression of the noradrenaline transporter (NAT), allowing
targeted radiotherapy using a radiolabeled structural analog
of noradrenaline, 131I-metaiodobenzylguanidine (MIBG).
This radiopharmaceutical has proven to be an excellent
palliative, and long-term remissions have been achieved
after single-agent treatment (15). However, the optimal
way to use 131I-MIBG has yet to be defined, and increas-
ingly it is administered in combination with other treat-
ments in attempts to exploit the expression of several
different targets in the rapidly evolving cells of tumors.
Future advances in 131I-MIBG therapy are expected to de-
rive from concurrent administration of radiosensitizers.
Drug resistance is also an important cause of failure in
the treatment of neuroblastoma, possibly caused by in-
creased P-glycoprotein expression after chemotherapy
(16). Disulfiram inhibits P-glycoprotein–mediated drug re-
sistance (17), thereby increasing sensitivity to chemothera-
peutic agents, and this approach has been used successfully
for treating pediatric tumors, including retinoblastoma and
neuroblastoma (18). Having previously demonstrated syn-
ergy between the topoisomerase I inhibitor topotecan and
131I-MIBG (19,20), we now describe the use of a similar
methodology to test the potential synergistic effect of di-
sulfiram with 131I-MIBG treatment.
We report an investigation of the extent to which disul-
firam’s ability to induce cell death occurred through copper-
or ROS-dependent mechanisms. In the SK-N-BE(2c) and
UVW/NAT cancer cell lines, clonogenic survival was
decreased by disulfiram treatment, and the presence
of copper was necessary for tumor cell kill at low, clini-
cally achievable, concentrations of disulfiram. Moreover,
the molar ratio of disulfiram to copper was critical for
cytotoxicity. Finally, a potent radiosensitizing effect of
disulfiram was demonstrated in vitro and in vivo for
the first time, to our knowledge, and this also was copper-
dependent.
MATERIALS AND METHODS
Reagents
Disulfiram (tetraethylthiuram disulfide) was purchased from
Sigma-Aldrich and Antabuse obtained from Actavis. Stock solu-
tions of both agents were prepared in dimethyl sulfoxide, and then
diluted in culture medium (maximum dimethyl sulfoxide concen-
tration, 0.1% v/v). All other drugs were dissolved in culture
medium. All cell culture medium and supplements were pur-
chased from Invitrogen, and all other chemicals were from Sigma-
Aldrich. No-carrier-added 131I-MIBG was prepared as described
previously (20).
Cell Culture
Human neuroblastoma–derived SK-N-BE(2c) cells were pur-
chased from the American Type Culture Collection. The UVW
cell line was derived from a human glioblastoma (21). Cell lines
were authenticated in-house using the AmpF/STR Identifiler kit
(Applied BioSystems). SK-N-BE(2c) cells were maintained in
Dulbecco modified Eagle medium containing 15% (v/v) fetal calf
serum. UVW cells were transfected to express the NAT gene as
previously described (22) and were maintained in minimum
essential medium ½AQ7containing 10% (v/v) fetal calf serum and genet-
icin (1 mg/mL) at 37C in a 5% CO2 atmosphere.
Clonogenic Survival Assay
Cells were seeded in 25-cm2 flasks at 105 cells per flask. When
cultures were in the exponential growth phase, medium was re-
moved and replaced with fresh medium containing disulfiram; the
cell-impermeable copper chelator bathocuproine disulfonic acid
(BCPD) (300 mM), the antioxidant N-acetyl-L-cysteine (NAC)
(1 mM), copper (II) chloride, or various combinations of these
agents were added simultaneously. Cells were incubated with
drugs for 24 h. Cells were g-irradiated using an Alcyon II 60Co-
cobalt source at a dose rate of 1 Gy/min, then incubated for 24 h.
For experiments conducted in serum-free conditions, cells were
washed twice with phosphate-buffered saline before the serum-
free medium with or without drugs was added. After drug treat-
ment, cells were seeded for clonogenic assay as previously
described (19,20).
Spheroid Growth Assay
Multicellular spheroids were used for the evaluation of 131I-
MIBG treatment because b-particle cross-fire irradiation makes
a considerable contribution to its efficacy. This component of
tumor cell kill would be underrepresented in cellular monolayers
(23). SK-N-BE(2c) and UVW/NAT cells were cultured as multi-
cellular tumor spheroids using the liquid overlay technique (24).
Briefly, spheroids were initiated by inoculating cells into an
agar-coated flask. After 3–4 d, spheroids were retrieved by centri-
fugation and resuspended in fresh serum-free culture medium con-
taining disulfiram or copper for 24 h. Simultaneously, 131I-MIBG
was added to the medium at a final concentration of 1 MBq/mL for
SK-N-BE(2c) and 0.5 MBq/mL for UVW/NAT spheroids. After
treatment, spheroids were washed twice and those of approxi-
mately 100 mm in diameter were transferred individually into
agar-coated wells of 24-well plates. Individual spheroid growth
was monitored twice per week using an inverted phase-contrast
microscope connected to an image acquisition system. Two per-
pendicular diameters, dmax and dmin, were measured using image
analysis software (ImageJ) and the volume, V (mm3), was calcu-
lated using the formula V 5 p ½AQ8· dmax · dmin2/6 (25).
Combination Treatments
The cytotoxic interaction between disulfiram and radiation was
examined using a clonogenic assay, according to the method of
Chou and Talalay (26). Initially, exponentially growing cells were
treated with each agent alone to determine effective doses. Cells
were subsequently treated with a range of doses of disulfiram and
g-radiation, administered simultaneously, using a fixed dose ratio
of disulfiram to g-radiation, so that the proportional contribution
of each agent in the mixtures would be the same at all treatment
intensities. The fixed dose ratio was 0.1 mM disulfiram to 0.9 Gy
of g-radiation, based on inhibitory concentration of 50% values of
0.34 mM and 3 Gy, for disulfiram and g-radiation, respectively.
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The effectiveness of combinations of disulfiram and g-radiation
was quantified by determining a combination index (CI) at various
levels of cytotoxicity. Because the method of interaction was un-
known, CI values were calculated assuming both mutual exclusiv-
ity (where the drugs have similar mechanisms of action) and
mutual nonexclusivity (where the drugs have dissimilar mecha-
nisms of action). CIs less½AQ9 than, equal to, and greater than 1 in-
dicate synergism, additivity, and antagonism, respectively.
Tumor Xenografts
Six-week-old female, congenitally athymic nude mice of strain
CD1 nu/nu were obtained from Charles River plc. In vivo experi-
ments were performed in accordance with the Animals (Scientific
Procedures) Act 1986. Tumors in athymic mice formed from
SK-N-BE(2c) and UVW/NAT cells express the NAT, enabling
active uptake of 131I-MIBG. Subcutaneous tumor growth was
established as previously described (19). Mice were used for ex-
perimental therapy when the SK-N-BE(2c) tumor volumes had
reached approximately 500 mm3 or when UVW/NAT tumors
had grown to approximately 60 mm3. To monitor potential toxic-
ity, experimental animals were examined daily for signs of distress
and weighed weekly. Mice were randomized into treatment
groups, each consisting of 6 animals that received phosphate-
buffered saline solution (intraperitoneal injection), disulfiram so-
lution (200 mg/kg; suspension in water, by oral gavage), 10 MBq
of 131I-MIBG (intraperitoneal injection), 5 Gy of g-radiation
or simultaneous administration of disulfiram and 131I-MIBG, or
disulfiram and g-radiation.½AQ10 The activity of 131I-MIBG given to
the mice was shown previously by us to induce a significant
delay of growth but incomplete sterilization of UVW/NAT
xenografts (19). Tumors were measured with calipers immedi-
ately before treatment and twice weekly thereafter. On the as-
sumption of ellipsoidal geometry, diameter measurements were
converted to an approximate tumor volume by multiplying half
the longest diameter by the square of the mean of the 2 shorter
diameters. Mice whose xenograft volume reached 1,900 mm3
were euthanized.
Statistics
Data are presented as mean 6 SEM, unless otherwise stated,
with the number of independent repetitions provided in the legend
to each figure. Statistical significance was determined using a Stu-
dent t test. A P value of less than 0.05 was considered to be
statistically significant and less than 0.01 highly significant.
RESULTS
Cytotoxicity of Disulfiram
Escalating concentrations of disulfiram caused a biphasic
toxicity profile in SK-N-BE(2c) cells ( ½Fig: 1Fig. 1). Initial clono-
genic kill was maximal after the administration of 1.7 mM
disulfiram. Increasing disulfiram beyond this concentration
resulted in partial reversal of cytotoxicity, up to 10 mM
disulfiram. Thereafter, cytotoxicity increased, and after
the administration of 17 mM disulfiram, clonogenic survival
was 10% of untreated control levels (Fig. 1A). The effect
on clonogenic survival of the clinical formulation of disul-
firam used in animal studies, Antabuse, was also evaluated.
A concentration-dependency profile similar to that gener-
ated by disulfiram was observed (Fig. 1A).
A glioma cell line transfected with the NAT gene, UVW/
NAT, responded in an analogous manner with respect to
clonogenic cell kill in response to a range of concentrations
of disulfiram (Fig. 1B). Again, the initial clonogenic survival
nadir was observed after treatment with 1.7 mM disulfiram.
A similar biphasic dose–toxicity profile was also observed
when UVW/NAT cells were exposed to Antabuse (Fig. 1B).
Biphasic Dose–Response of Disulfiram
Treatment with 1 mM of the antioxidant NAC alone had
no significant effect but prevented the reduction in clono-
genic survival of SK-N-BE(2c) cells and UVW/NAT cells
induced by concentrations of disulfiram greater than 10 mM,
whereas NAC had no significant effect on disulfiram-induced
toxicity at concentration of 10 mM or less (Fig. 1). There-
fore, a ROS-independent mechanism of cell kill predomi-
nated at low concentrations of disulfiram (#10 mM).
Although BCPD alone had no significant effect, the
disulfiram-induced reduction in clonogenic survival of SK-
N-BE(2c) cells was prevented by BCPD, at 300 mM, in the
first phase of the dose–response, up to and including 10 mM
disulfiram, suggesting a role for copper in disulfiram-
induced cytoxicity at low concentrations. Although UVW/
NAT cells were more resistant to disulfiram, the initial,
maximal, clonogenic cell kill observed after treatment with
1.7 mM disulfiram was also prevented by BCPD ( ½Fig: 2Fig. 2B).
FIGURE 1. Cytotoxicity of disulfiram is bi-
phasic with respect to dose. Clonogenic
survival after exposure of SK-N-BE(2c) cells
(A) or UVW/NAT cells (B) to disulfiram for
24 h in absence or presence of NAC or to
clinical formulation of disulfiram (Antabuse);
n 5 4. Data are mean 6 SEM. Significance
of differences: *P , 0.05. **P , 0.01 from
untreated control. †P , 0.05 from disul-
firam alone. conc. 5 concentration; DSF 5
disulfiram.
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Effect of Copper on Cytotoxicity of Disulfiram
In serum-free medium and in the absence of copper,
disulfiram, at concentrations up to 10 mM, induced no
significant reduction in survival of either SK-N-BE(2c) or
UVW/NAT clonogens (½Fig: 3 Fig. 3), whereas the inclusion of
copper chloride in the incubation medium resulted in
dose-dependent clonogenic cell kill. This½AQ11 was maximal
when disulfiram and copper concentrations were equimolar
(Fig. 3). These observations suggest not only that the pres-
ence of copper is important for the cytotoxicity of disulfi-
ram, but also that the concentration of copper relative to
disulfiram is a major determinant of disulfiram’s potency.
Copper Dependence of Disulfiram Radiosensitization
To investigate the potential for disulfiram to act as
a radiosensitizer, SK-N-BE(2c) cells were g-irradiated
alone or in combination with disulfiram. A radiation dose
response was clearly demonstrated with enhancement of the
radiation-induced clonogenic kill by disulfiram at all radi-
ation doses (½Fig: 4 Fig. 4). Inhibitory concentration of 50% values
of 3.23 or 1.88 Gy were observed in the absence or pres-
ence of disulfiram, respectively. The effective doses of di-
sulfiram and radiation were estimated from dose responses
of each agent alone. A constant dose ratio of 1:9 of disul-
firam (mM) to g-irradiation (Gy) was used in the combina-
tion experiments. The CI values were determined according
to the study of Chou and Talalay (26) and are shown in
½Table 1Table 1. Because the manner of the interaction between the
agents was uncertain, the formula was solved in 2 different
ways, corresponding to modes of action of the 2 agents,
which are similar or distinct. Synergistic kill of SK-N-BE
(2c) clonogens after treatment with combined disulfiram
and g-irradiation was manifested by CI values less than 1
for all dose intensities examined. For example, at the ED30
(dose required to kill 30% of clonogens), CI values were
0.45 6 0.12 or 0.68 6 0.19, assuming mutually exclusive
or independent modes of action, respectively. Correspond-
ing CI values at the ED50 ½AQ12(dose required to kill 50% of
clonogens) were 0.62 6 0.14 and 0.70 6 0.19, respectively ½AQ13,
and at the ED90 (dose required to kill 90% of clonogens)
values were 0.70 6 0.15 and 0.80 6 0.2, respectively. In-
creasing CI values suggest decreasing synergism at higher
dose intensities. Nonetheless, the observation of CI values
less than 1 throughout the toxicity range of the experimen-
tal combination therapy indicated synergy at all strengths of
treatment.
The involvement of copper in the radiosensitizing action
of disulfiram was investigated by clonogenic assay of cells
treated with combinations of disulfiram and g-radiation in
the presence or absence of serum, BCPD, or copper chlo-
FIGURE 2. Copper is necessary for toxic-
ity of disulfiram at concentrations , 4 mM.
Clonogenic survival after exposure of SK-N-
BE(2c) cells (A) or UVW/NAT cells (B) to di-
sulfiram for 24 h in absence or presence of
BCPD; n 5 5. Data are mean 6 SEM. Sig-
nificance of differences: *P , 0.05. **P ,
0.01 from untreated control. †P , 0.05 from
disulfiram alone. conc. 5 concentration.
FIGURE 3. Clonogenic cell kill is depen-
dent on relative concentrations of disulfiram
and copper. Clonogenic survival after expo-
sure of SK-N-BE(2c) cells (A) or UVW/NAT
cells (B) to disulfiram for 24 h in absence or
presence of CuCl2 in serum-free medium;
n 5 4. Data are mean 6 SEM. Significance
of differences from untreated controls: *P ,
0.05. **P , 0.01. conc. 5 concentration.
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ride. The clonogenic survival of g-irradiated SK-N-BE(2c)
cells was not significantly affected by the removal of serum
or incubation with BCPD or copper chloride. Clonogenic
cell kill resulting from treatment with 0.34 mM disulfiram
was prevented by the removal of serum (P , 0.05) or in-
clusion of BCPD (P , 0.05) and enhanced by the addition
of copper chloride (P , 0.05) (½Fig: 5 Fig. 5). Furthermore, the
enhanced clonogenic kill induced by combined disulfiram
and radiation treatment relative to single-agent treatment
was prevented by serum removal (P , 0.05) or addition
of BCPD (P , 0.05). In contrast, incubation with copper
resulted in potentiation of the cell kill achieved by the
disulfiram and radiation combination (P , 0.05).
Effect of Disulfiram and 131I-MIBG on Spheroid
Growth Delay
Copper chloride alone had no effect on the growth rate of
spheroids composed of SK-N-BE(2c) or UVW/NAT cells,
whereas disulfiram alone (at 33.7 mM) decreased the
growth rate of SK-N-BE(2c) and UVW/NAT spheroids.
The evaluation of a range of equimolar doses of disulfiram
and copper indicated that treatment of spheroids with 3.37 mM
induced growth delay but not sterilization (Supplemental
Fig½AQ14 . 1; supplemental materials are available online only at
http://jnm.snmjournals.org). Therefore, 3.37 mM (equimo-
lar doses of disulfiram and copper )½AQ15 was the concentration
used in subsequent evaluation of enhancement of cell kill
by 131I-MIBG targeted radiation.
Using relative spheroid volume on the last day of mea-
surement as an index of efficacy, single-agent 131I-MIBG
treatment reduced spheroid growth to 54% and 87% of
control for SK-N-BE(2c) and UVW/NAT spheroids, respec-
tively. Similarly disulfiram and copper reduced growth to
69% and 58% of control volume for SK-N-BE(2c) and
UVW/NAT spheroids, respectively. In contrast, the com-
bined treatment with 131I-MIBG and disulfiram–copper
sterilized all the SK-N-BE(2c) and UVW/NAT spheroids;
this sterilization½AQ16 result manifested as a failure to increase
in size throughout the duration (20 d for SK-N-BE(2c) or
22 d for UVW/NAT spheroids) of the experiments (½Fig: 6 Fig. 6).
Antitumor Activity of Disulfiram and Radiation
The antitumor effect of disulfiram alone or in combina-
tion with radiation treatment was studied in vivo using
subcutaneous tumor xenografts grown in athymic mice.
None of the animals in this study showed signs of distress.
Alternative radiation modalities were examined: external-
beam g-rays from a 60Co-cobalt source and the NAT-seeking
radiopharmaceutical 131I-MIBG administered by intraperito-
neal injection.
Although disulfiram alone had no significant effect on
tumor growth, the growth inhibitory effect of g-radiation or
131I-MIBG was enhanced by combination treatment with
disulfiram in both tumor types ( ½Fig: 7Fig. 7). The times after
treatment for 4-fold (SK-N-BE(2c)) or 10-fold (UVW/
NAT) increase in tumor volume are shown in ½Table 2Table 2.
These results indicate that combination treatment with di-
sulfiram and radiation produced a greater tumor growth
delay than either agent alone, and this delay ½AQ17was apparent
in 2 different xenograft models and using 2 different sour-
ces of radiation.
DISCUSSION
In response to treatment of neuroblastoma and glioma
cells with disulfiram, we observed a biphasic pattern of
clonogenic cell kill. Similar dose–response patterns have
been reported in disulfiram-treated myeloma cells (27), in
murine leukemia cell lines incubated with the reduced form
of disulfiram (diethyldithiocarbamate) (28), and in pheo-
chromocytoma cells treated with the structurally related
compound pyrrolidine dithiocarbamate (PDTC) (29).
It has been suggested that many of the effects of
disulfiram are due to its ability to induce oxidative stress.
For example, disulfiram depleted antioxidant levels in rat
cortical astrocytes (2) and elevated ROS levels in mela-
noma cells (3). Moreover, the toxicity of disulfiram to mel-
anoma cells was prevented by exogenous antioxidants (3).
In the present study, the antioxidant NAC prevented the
reduction in clonogenic survival induced only by high con-
centrations (.10 mM) of disulfiram but had no effect on
disulfiram-induced toxicity at lower concentrations. Clini-
cal studies have indicated that after a single oral dose of
500 mg, or repeated doses of 250 mg, plasma concentra-
tions of disulfiram were less than 2 mM (30,31). Therefore,
a ROS-independent mechanism is expected to predominate
at clinically achievable concentrations of disulfiram.
PDTC is structurally similar to disulfiram and has been
shown to cause serum-dependent apoptosis of breast tumor
FIGURE 4. Effect of disul-
firam on radiosensitivity of
SK-N-BE(2c) cells. Clonogenic
survival was determined after
exposure of cells to g-radia-
tion alone or simultaneously
with 0.34 mM disulfiram (n 5
4) after correcting for plating
efficiency and disulfiram cyto-
toxicity alone. Data are mean6
SEM. DSF 5 disulfiram.
TABLE 1
Effect of Disulfiram and g-Radiation on CIs
Effect level Mutually exclusive Mutually nonexclusive
ED30 0.45 6 0.12 0.68 6 0.19
ED40 0.61 6 0.14 0.69 6 0.19
ED50 0.62 6 0.14 0.70 6 0.19
ED70 0.64 6 0.14 0.73 6 0.20
ED90 0.70 6 0.15 0.80 6 0.21
CI values are mean 6 SEM of 4 experiments. EDnn 5 dose
required to kill nn% of clonogens. ½AQ24
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cells (32). We also observed that the presence of serum was
necessary for disulfiram-induced toxicity at low (,10 mM)
disulfiram concentrations. The toxicity of some metal-
chelating compounds, including disulfiram, may be depen-
dent on the presence of metal ions such as copper (33), and
high copper concentrations have been noted in commer-
cially prepared fetal calf serum (34). Therefore, it is possi-
ble that the presence of copper in serum was, at least partly,
responsible for the serum-dependent disulfiram toxicity.
Disulfiram-induced toxicity to rat astrocytes was pre-
vented by the cell-impermeable copper chelator BCPD (2).
We also observed the inhibition of clonogenic cell kill, at
disulfiram concentrations less than 10 mM, by the inclusion
in the medium of BCPD, suggesting a role for copper in
disulfiram-induced cytotoxicity. At concentrations of disul-
firam greater than 10 mM, the ROS-dependent cytotoxic
effect predominated. Similarly, PDTC-induced apoptosis
of breast cancer cells was also suggested to be a result of
its copper-binding activity (35).
The reduced potency of disulfiram resulting from BCPD
treatment was similar to that observed in response to in-
cubation with serum-free medium, suggesting that serum in
the medium was sufficient and necessary for the disulfiram-
induced toxicity. The inclusion of exogenous copper in the
incubation medium was sufficient to reinstate the toxic
effect of disulfiram in the absence of serum, whereas
BCPD, in molar excess relative to disulfiram, prevented
the toxic effect of copper, presumably by competing with
disulfiram for extracellular copper binding.
Clonogenic cell kill was maximal when disulfiram and
copper concentrations were equimolar. Increasing concen-
tration of disulfiram in molar excess of copper progres-
sively reduced the cytotoxic effect of the disulfiram–copper
complex, suggesting that the concentration of copper rela-
tive to disulfiram is crucial with respect to cytotoxicity.
The increased potency of disulfiram observed in the pres-
ence of serum may also be explained by copper chelation.
Serum contains approximately 15 mM copper (36). There-
fore, cells cultured in 10% or 15% (v/v) serum would be
exposed to 1.5 or 2.3 mM copper. In serum-containing me-
dium, the greatest cell kill resulting from disulfiram treat-
ment occurred at 1.7 mM. This observation is consistent
with the requirement for copper chelation for optimal ef-
fectiveness of disulfiram. It also suggests that there would
be sufficient copper in human and murine serum to allow
the formation of effective levels of the disulfiram–copper
complex.
Similarly, it has been observed that the toxicity of
disulfiram to Salmonella typhimurium was increased by
the elevation of copper sulphate levels to equimolar con-
centration but was decreased in the presence of excess di-
sulfiram (37). The presence of surplus disulfiram may result
in competition between free disulfiram and disulfiram–
copper complexes for cellular uptake or intracellular bind-
ing. This competition for targets may then explain the effect
of increasing survival observed with increasing disulfiram
concentration above copper concentration.
The dithiocarbamates disulfiram and PDTC have been
reported to be effective inhibitors of proteasome activity
(5), especially when complexed with copper (6). Because
the proteasome plays a pivotal role in the control of cell
cycle progression and survival after potentially toxic insult,
proteasome inhibitors are regarded as promising anticancer
agents. They can induce apoptosis as a consequence of the
accumulation of undegraded proteins and the prevention of
NF-kB activation. Disulfiram also facilitates copper uptake
FIGURE 5. Enhancement of
radiation cell kill by disulfiram
requires copper. Clonogenic
survival after exposure of SK-
N-BE(2c) cells to 0.34 mM di-
sulfiram, 3 Gy g-radiation, or
a combination of both treat-
ments in serum-containing
medium, serum-containing me-
dium with 300 mM BCPD, se-
rum-free medium, or serum-free
medium containing 1 mM
CuCl2; n 5 3. Data are mean
6 SEM. Significance of differ-
ences: *P , 0.05. **P , 0.01 from untreated control. †P , 0.05.
††P , 0.01 from g-irradiation alone. DSF 5 disulfiram.
FIGURE 6. Disulfiram enhances delay of
spheroid growth induced by 131I-MIBG. Mul-
ticellular spheroids derived from SK-N-BE
(2c) (A) or UVW/NAT cells (B) were treated
with disulfiram plus CuCl2 (3.37 mM), 131I-
MIBG (1 MBq/mL for SK-N-BE(2c) and 0.5
MBq/mL for UVW/NAT), or a combination of
both. Data are expressed as mean spheroid
volume at every time point divided by origi-
nal volume (V/V0) 6 SD of 13–23 spheroids
per treatment. DSF 5 disulfiram.
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(33), increasing its intracellular availability. Therefore,
it appears that disulfiram has potential as an anticancer
agent. In particular, the absence of antitumor effect by di-
sulfiram administered as a single agent as opposed to its
enhancement of radiotoxicity suggests that the efficacy of
disulfiram should be characterized by tumor specificity
and minimal damage to tissues that fail to accumulate
radiopharmaceutical.
It has been suggested that proteasome inhibitors may be
effective radiosensitizers (13). Therefore, it is possible that
disulfiram or its metabolites have radiosensitizing proper-
ties. Indeed, diethyldithiocarbamate has previously been
shown to enhance radiation sensitivity in rapidly prolifer-
ating cells (14). We observed that disulfiram acted syner-
gistically with g-radiation to potentiate clonogenic cell kill
at all levels of toxicity. The clonogenic survival of cells
exposed to g-radiation was not affected by removal of se-
rum or the addition of BCPD or copper(II) chloride, indi-
cating that radiation-induced clonogenic cell kill was not
copper-dependent. Conversely, clonogenic cell kill by di-
sulfiram at 0.34 mM, a concentration previously shown to
inhibit proteasome activity in cell-based assays (5), was
prevented by removal of serum or addition of BCPD and
enhanced by copper supplementation. Moreover, the en-
hanced clonogenic cell kill resulting from combined disul-
firam and g-radiation treatment was prevented by serum
removal or incubation with BCPD, whereas the addition
of copper reinstated the toxicity of g-radiation combined
with disulfiram in serum-free conditions. This½AQ18 suggests that
copper was necessary for radiosensitization by disulfiram.
CONCLUSION
We have demonstrated½AQ19 in vitro and for the first, time to
our knowledge, in vivo that disulfiram acted as a radiosensi-
tizer. The effect of disulfiram alone was less appreciable in
spheroids than in monolayers. Resistance associated with
aggregates of cells is a commonly observed effect and has
been attributed to intercellular linkage; interactions be-
tween cell and matrix; and limited penetration resulting
in gradients of oxygen, nutrients, and drugs (38).½AQ20 Disulfi-
ram did, however, enhance the radiation-induced delay of
the growth of spheroids derived from 2 different tumor cell
lines and retarded the growth of 2 human tumor xenografts
in athymic mice. Disulfiram ½AQ21not only enhanced the antitu-
mor efficacy of g-radiation delivered from an external
source but also potentiated the efficacy of 131I-MIBG tar-
geted radionuclide therapy, in both spheroid and xenograft
models. Significantly, the synergistic activity in vivo was
achieved at a disulfiram dosage that had negligible effect
on xenograft tumor growth and has previously been dem-
onstrated to be associated with insignificant side effects
(9). Such features are highly desirable in a radiosensitizing
agent (39). The positive interaction between disulfiram and
131I-MIBG is worthy of further investigation.
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QUERIES - jnm113324q
[AQ1] Does NAT here stand for noradrenaline transporter as well?
[AQ2] In the original, “an inhibitor” here had a striketrough. Should this be deleted?
[AQ3] Because Antabuse is mentioned in the Materials and Methods section, with manufacturer given there, it was
deleted here.
[AQ4] Please verify the data in any tables and figures, and please confirm that any radiation or radiopharmaceutical
doses mentioned in the article are correct.
[AQ5] Please spell out NF-kB .
[AQ6] Please confirm that “Many tumors. . .” retains your meaning.
[AQ7] Please confirm that MEM has been spelled out properly.
[AQ8] What does p stand for here?
[AQ9] Please confirm that “CIs less than. . .” retains your meaning.
[AQ10] Please note the final punctuation separating “disulfiram and 131I-MIBG, or disulfiram and g-radiation” --
correctly punctuated as meant?
[AQ11] For “this" here, ok to edit as “cell kill”?
[AQ12] ED50 here and ED90 a few lines down also need a definition; please confirm accuracy of the ones given.
[AQ13] Here and 2 lines down, “respectively” has been added.
[AQ14] This part of the information “data supplied but not shown” has been deleted from the text and from the actual
supplemental figure. Ok as edited?
[AQ15] Does “.37 mM (equimolar doses of disulfiram and copper )” retain your meaning?
[AQ16] Please confirm that “. . .UVW/NAT spheroids; this sterilization . . .” retains your meaning.
[AQ17] “and this delay” ok as edited?
[AQ18] For “This” here, ok to change to “This result” or “finding”?
[AQ19] Per JNM style, a Conclusion heading should be added. Correct to add here, at “We have demonstrated. . .” as has
been done?
[AQ20] If the Conclusion heading should be for this paragraph containing references 38 and 39, per JNM style, no new
refs should be introduced in the Conclusion. Can 38 and 39 be deleted or can the sentences containing these
citations be moved to fall before the Conclusion?
[AQ21] Please confirm that “Disulfiram not only. . .” retains your meaning.
[AQ22] Medline indexes “Int J Cancer” but cannot find a listing for reference 5 “Lovborg, Oberg, Rickardson, Gullbo,
Nygren, Larsson, 2005”. Please check the reference for accuracy.
[AQ23] Medline indexes “Eur J Cancer” but cannot find a listing for reference 18 “Chan, Grogan, DeBoer, Haddad,
Gallie, Ling, 1997”. Please check the reference for accuracy.
[AQ24] So that each ED % value does not have to be spelled out in the table itself, ok to use something like “EDxx . . ."
as has been done in a footnote for the table? They’re ED30, 50, and 90 are used only once each in the text, and
typically JNM style requires abbreviations to be spelled out if they’re used fewer than 5 times. Please advise.
[AQ25] Please note that Table 2 and the footnote have been slightly modified.
